Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
Roche stock down 5% after disappointing drug trial data update
September 11, 2024 1:22 PM EDTRoche (OTC: RHHBY) shares dropped 5.4% on Wednesday following an update about the early-stage trial of its weight-loss pill, CT-996.
The Swiss pharmaceutical giant said in July that the experimental pill resulted in a 6.1% placebo-adjusted weight loss over four weeks in a Phase I trial, creating optimism around its potential.... More



